After market announcement. Tomorrow should be good.
ASX ANNOUNCEMENT 8 NOVEMBER 2004
BIONOMICS’ GENE-SILENCING MOLECULES INHIBIT TUMOUR GROWTH IN BREAST CANCER MODEL 8-Nov-2004
Results to be presented at international scientific symposia
Follows publication of earlier work in Proceedings of the National Academy of Science (USA)
Bionomics Limited (ASX:BNO, BNOOA, US OTC: BMICY) announced today that it has new data which shows that gene-silencing molecules developed by the Company inhibit tumour growth in a breast cancer model. The gene-silencing molecules target BNO69, one of Bionomics’ proprietary drug targets.
Bionomics’ Director of Cancer Research, Dr Gabriel Kremmidiotis will present these results at two scientific symposia in the United States this week.
Tumours that were treated with BNO69 gene-silencing molecules showed a reduction in size of over 75% compared to untreated tumours, in experiments conducted over 34 days. This result shows that BNO69 gene-silencing molecules have a profound effect on tumour growth and that BNO69 is potentially an effective drug target for treating breast cancer.
Dr Kremmidiotis said, “We have previously shown that BNO69 silencing is effective in inhibiting angiogenesis and that it has advantages over other angiogenesis drug targets because it operates at a point where two signalling pathways converge. What we have now shown is exciting because it establishes that targeting BNO69 is not only effective at inhibiting angiogenesis but also at curtailing breast cancer growth in this model.”
Angiogenesis is a physiological process of formation of new blood vessels. In adults it is involved in the growth of solid cancers as well as inflammatory disorders such as rheumatoid arthritis and complications of diabetes. Recent clinical successes in cancer with drugs which inhibit angiogenesis, have intensified the interest in this area. Industry estimates suggest that diseases that may be treated by angiogenesis based therapies encompass 20 percent of the US$320 billion global pharmaceutical market.
Dr Kremmidiotis will present to a conference focussed on research and development of Vascular Targeting Agents in Cambridge on Monday, 8th November and the Discovery on Target conference in Boston on Friday, 12th November. He will also present aspects of Bionomics’ Angene™ platform for the discovery and evaluation of anti-angiogenesis therapies and Bionomics’ proprietary Angene™ drug targets.
Bionomics’ proprietary BNO69 drug target and the BNO69 gene-silencing molecules are covered by Bionomics’ international patent applications, which are under examination in major world markets.
FOR FURTHER INFORMATION PLEASE CONTACT: DR DEBORAH RATHJEN CEO & MANAGING DIRECTOR BIONOMICS LIMITED Ph: +61 8 8354 6101
BNO Price at posting:
0.0¢ Sentiment: LT Buy Disclosure: Held
